These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33990592)

  • 1. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia.
    Ochi Y; Yoshida K; Huang YJ; Kuo MC; Nannya Y; Sasaki K; Mitani K; Hosoya N; Hiramoto N; Ishikawa T; Branford S; Shanmuganathan N; Ohyashiki K; Takahashi N; Takaku T; Tsuchiya S; Kanemura N; Nakamura N; Ueda Y; Yoshihara S; Bera R; Shiozawa Y; Zhao L; Takeda J; Watatani Y; Okuda R; Makishima H; Shiraishi Y; Chiba K; Tanaka H; Sanada M; Takaori-Kondo A; Miyano S; Ogawa S; Shih LY
    Nat Commun; 2021 May; 12(1):2833. PubMed ID: 33990592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia.
    Ma CC; Chai Y; Chen HL; Wang X; Gao Y; Hu WL; Xiang X
    J Int Med Res; 2020 May; 48(5):300060520919237. PubMed ID: 32366154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
    Barbouti A; Ahlgren T; Johansson B; Höglund M; Lassen C; Turesson I; Mitelman F; Fioretos T
    Br J Haematol; 2003 Jul; 122(1):85-93. PubMed ID: 12823349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic landscape of chronic myeloid leukemia.
    Ochi Y
    Int J Hematol; 2023 Jan; 117(1):30-36. PubMed ID: 36477676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KIT.
    Shoumariyeh K; Hussung S; Niemöller C; Bleul S; Veratti P; Follo M; Riba J; Philipp U; Palmer JM; Pfeifer D; Pantic M; Meggendorfer M; Hackanson B; Finke J; Haferlach T; Duyster J; Miething C; Becker H; von Bubnoff N
    Br J Haematol; 2020 Sep; 190(6):e339-e343. PubMed ID: 32579287
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical significance of clonal evolution in chronic myeloid leukemia].
    Ochi Y
    Rinsho Ketsueki; 2023; 64(5):369-375. PubMed ID: 37271527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
    Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
    Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.
    Zhao LJ; Wang YY; Li G; Ma LY; Xiong SM; Weng XQ; Zhang WN; Wu B; Chen Z; Chen SJ
    Blood; 2012 Mar; 119(12):2873-82. PubMed ID: 22318203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.
    Adnan Awad S; Dufva O; Ianevski A; Ghimire B; Koski J; Maliniemi P; Thomson D; Schreiber A; Heckman CA; Koskenvesa P; Korhonen M; Porkka K; Branford S; Aittokallio T; Kankainen M; Mustjoki S
    Leukemia; 2021 Apr; 35(4):1087-1099. PubMed ID: 32782381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Cortes JE; Jorgensen JL; Wang W; Yin CC; You MJ; Jabbour E; Kantarjian HM; Medeiros LJ; Hu S
    Leukemia; 2016 Jul; 30(7):1606-9. PubMed ID: 26837843
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Chen Z; Shao C; Wang W; Zuo Z; Mou X; Hu SJ; DiGiuseppe JA; Zu Y; Medeiros LJ; Hu S
    Leukemia; 2017 Mar; 31(3):585-592. PubMed ID: 27560111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
    Roche-Lestienne C; Deluche L; Corm S; Tigaud I; Joha S; Philippe N; Geffroy S; Laï JL; Nicolini FE; Preudhomme C;
    Blood; 2008 Apr; 111(7):3735-41. PubMed ID: 18202228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
    Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
    Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.
    Sakai K; Ishikawa Y; Mori Y; Kobayashi M; Iriyama C; Ozawa Y; Suzuki T; Minami Y; Ishikawa K; Kaneda N; Naoe T; Kiyoi H
    Int J Hematol; 2011 Feb; 93(2):237-242. PubMed ID: 21264552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
    Schmidt M; Rinke J; Schäfer V; Schnittger S; Kohlmann A; Obstfelder E; Kunert C; Ziermann J; Winkelmann N; Eigendorff E; Haferlach T; Haferlach C; Hochhaus A; Ernst T
    Leukemia; 2014 Dec; 28(12):2292-9. PubMed ID: 25212276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.
    Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S
    Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.
    Ko TK; Javed A; Lee KL; Pathiraja TN; Liu X; Malik S; Soh SX; Heng XT; Takahashi N; Tan JHJ; Bhatia R; Khng AJ; Chng WJ; Sia YY; Fruman DA; Ng KP; Chan ZE; Xie KJ; Hoi Q; Chan CX; Teo ASM; Velazquez Camacho O; Meah WY; Khor CC; Ong CTJ; Soon WJW; Tan P; Ng PC; Chuah C; Hillmer AM; Ong ST
    Blood; 2020 Jun; 135(26):2337-2353. PubMed ID: 32157296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.